



Austrian
Federal Office for
Safety in Healthcare
BASG

PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

Procamidor – 20 mg/ml Solution for Injection

AT/V/0011/001

Date: 08/10/2013

Update: 05/03/2024

MODULE 1

PRODUCT SUMMARY

EU Procedure number	AT/V/0011/001/MR
Name, strength and pharmaceutical form	Procamidor 20 mg/ml solution for injection [AT, CZ, DE, EE, ES, IT, LT, LV, NL, PT, RO, SI, SK] Procamidor vet. 20 mg/ml solution for injection [FI, DK, IS, NO, SE] Procamidor solution for injection [FR]
Applicant	Richter Pharma AG Feldgasse 19 4600 Wels - Austria
Active substance	Procaine hydrochloride
ATC Vetcode	QN01BA02
Target species	Horse, cattle, pig, sheep, dog, cat.
Indication for use	<ul style="list-style-type: none">- Infiltration anaesthesia in horses, cattle, pigs, sheep, dogs and cats- Conduction anaesthesia in dogs and cats- Epidural anaesthesia in cattle, sheep, pigs and dogs

MODULE 2

The Summary of Product Characteristics (SPC) for this product is available on the Heads of Veterinary Agencies website (www.hma.eu).

MODULE 3

PUBLIC ASSESSMENT REPORT

Legal basis of original application	Generic application art. 13(1)
Date of completion of the original mutual recognition procedure	25/09/2013
Concerned Member States for procedure	CZ, DE, DK, EE, ES, FI, FR, IS, IT, LT, LV, NL, NO, PT, RO, SE, SI, SK.

I. SCIENTIFIC OVERVIEW

The product is produced and controlled using validated methods and tests, which ensure the consistency of the product released on the market.

It has been shown that the product can be safely used in the target species; the slight reactions observed are indicated in the SPC.

The product is safe for the user, the consumer of foodstuffs from treated animals and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.

The efficacy of the product was demonstrated according to the claims made in the SPC.

The overall risk/benefit analysis is in favour of granting a marketing authorisation.

II. QUALITY ASPECTS

II.A Composition

The product contains Procaine hydrochloride 20.00 mg/ml as active substance and the excipients Sodium methyl parahydroxybenzoate, Sodium metabisulfite, Disodium edetate, Sodium chloride, Hydrochloric acid and water for injection.

The container/closure systems are 100 ml clear glass vials, type II, with bromobutyl rubber stopper and aluminium crimp cap.

The particulars of the containers and controls performed are provided and conform to the regulation.

The choice of the formulation and the presence of the preservative are justified.

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

II.B Method of Preparation of the Product

The product is manufactured fully in accordance with the principles of good manufacturing practice from a licensed manufacturing site.

Process validation data on the product have been presented in accordance with the relevant European guidelines.

II.C Control of Starting Materials

The active substance is Procaine hydrochloride, an established active substance which is described in the European Pharmacopoeia. Supporting data have been provided in the form of an Active Substance Master File (ASMF). It is considered that the manufacturing process is adequately controlled and the active substance specification has been suitably justified.

All the excipients are the subject of monographs in the European Pharmacopoeia and are provided to that standard.

II.D Specific Measures concerning the Prevention of the Transmission of Animal Spongiform Encephalopathies

There are no substances within the scope of the TSE Guideline present or used in the manufacture of this product.

II.E Control on intermediate products

Not applicable.

II.F Control Tests on the Finished Product

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product.

Satisfactory validation data for the analytical methods have been provided.

Batch analytical data from the proposed production site have been provided demonstrating compliance with the specification.

II.G Stability

Stability data on the active substance have been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions.

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its proposed shelf life when stored under the approved conditions.

An in-use stability of 28 days is supported.

II.H Genetically Modified Organisms

Not applicable.

II.J Other Information

None.

III. SAFETY AND RESIDUES ASSESSMENT (PHARMACO-TOXICOLOGICAL)

III.A Safety Testing

Pharmacological Studies

Since the application is made in accordance with Article 13(1) of Directive 2001/82/EC, as amended, for a generic veterinary medicinal product, data on pharmacodynamics and pharmacokinetics are not required. The data submitted are in accordance with the requirements of the applicable European bioequivalence guideline.

Toxicological Studies

Since the application is made in accordance with Article 13(1) of Directive 2001/82/EC, as amended, for a generic veterinary medicinal product, this information is not required.

User Safety

Since the application is made in accordance with Article 13(1) of Directive 2001/82/EC, as amended, a detailed user safety is not required.

Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product.

Ecotoxicity

The applicant provided a first phase environmental risk assessment in compliance with the relevant guideline which showed that no further assessment is required.

Warnings and precautions as listed on the product literature are adequate to ensure safety to the environment when the product is used as directed.

III.B Residues documentation

No residue depletion studies were conducted because, in accordance with the data requirements of the applicable European bioequivalence guideline, it was demonstrated that the product is a generic of "Procaine hydrochloride 2% - VMD, 20 mg/ml solution for injection" and that the residue depletion profile will be the same.

MRLs

Procaine hydrochloride and all excipients are listed in Table 1 of Council Regulation 37/2010. No MRLs were set.

Withdrawal Periods

Based on the data provided above, withdrawal periods of zero days for meat and offal and zero hours for milk are justified.

IV. CLINICAL ASSESSMENT (EFFICACY)

IV.A Pre-Clinical Studies

Pharmacology

Since the application is made in accordance with Article 13(1) of Directive 2001/82/EC, as amended, for a generic veterinary medicinal product, this information is not required as it has already been presented for the reference product.

Tolerance in the Target Species of Animals

Since the application is made in accordance with Article 13(1) of Directive 2001/82/EC, as amended, for a generic veterinary medicinal product, this information is not required as it has already been presented for the reference product.

IV.B Clinical Studies

Laboratory Trials

Since the application is made in accordance with Article 13(1) of Directive 2001/82/EC, as amended, for a generic veterinary medicinal product, this information is not required as it has already been presented for the reference product.

V. OVERALL CONCLUSION AND BENEFIT- RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.

MODULE 4

POST-AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the veterinary Heads of Agencies website (www.hma.eu).

This section contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

Significant changes

Summary of change (Application number)	Approval date
This marketing authorization was renewed unlimited. (AT/V/0011/001/R/001)	08/08/2017
*** No significant changes since ***	